4Hoshi S,Yoshitomi H,Komatsu N,et al.Megakaryocytopoietic activity of a truncated variant of mouse thrombopoietin[J].Bio-chem Biophys Res Commun,1997,231(1):823-826.
6Nomura S,Kazuo D,Tomomitsu H,et al.Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with id-iopathic thrombocytopenic purpura[J].Blood,2002,100(3):728-730.
6Vadhan-Raj S,Murray L J,Bueso-Ramos C et al.Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patinents with cancer.Ann Intern Med,1997,126: 678
7Hoshi S,Yoshitomi H,Komatsu N et al.Megakaryocytopoietic activity of a truncated variant of mouse thrombopietin.J Biophys Commun,1997,231: 823
8O'Malley C J,Rasco J E,Basser R L et al.Administration of PEG-rHuMGDF to human stimulates the production of functional platelets that show no evidence of in vivo activiation.Blood ,1996,88: 3288
9Harker L A,Roskos J E,Marzec U M et al.Effects of megakaryocyte growth and development factor on platelet production,platelet life span,and platelet function in healthy human volunteers.Blood,2000,95: 2514
5Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of ter- minology, definitions and outcome criteria in immune thrombocy- topenic purpura of adults and children: report from an international working group[J].Blood, 2009, 113( 11 ) : 2 386-2 393.
